TRIANA Biomedicines Announces Participation in Upcoming Investor Conferences
Lexington, MA – September 2, 2026 – TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, today announced that management will participate in the following upcoming investor conferences:
Cantor Global Healthcare Conference
Participant: Patrick Trojer, PhD, President and Chief Executive Officer of TRIANA Biomedicines
Location: New York, New York
Date: September 9, 2026
Goldman Sachs Life Science Symposium
Participant: Patrick Trojer, PhD, President and Chief Executive Officer of TRIANA Biomedicines
Location: New York, New York
Date: September 15, 2026
About TRIANA Biomedicines, Inc.
TRIANA Biomedicines is a private biotechnology company, headquartered in Lexington, Massachusetts, focused on building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. TRIANA’s drug discovery engine is powered by bespoke chemical libraries, deep biochemical and biological mechanistic insights in addition to high resolution structural biology. TRIANA’s target-first and proximity-first approach to molecular glue discovery is currently focused on inducing or enhancing the degradation of high-profile disease targets. The therapeutic approach pioneered by TRIANA has the potential to fundamentally change the paradigm of small molecule drug discovery and bring significant therapeutic benefits to patients.
Contact